Drug, bio-affecting and body treating compositions inventions 02/08

20080050309 - Compositions of pharmaceuticals for use in low energy neutron therapy: A saccharide with a ring sulfur atom can participate more readily in biological processes than a sugar with a ring oxygen atom, and such thiosaccharides possess unique physiochemical properties that include penetration of a viscous lipid bilayer membrane of a cancer cell, and resistance to reduction by enzymes, enabling retention... Agent: Zbigniew Janusz Witczak

20080050314 - Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 beta (gsk3b): The invention provides a human GSK3B which is associated with cardiovascular diseases, cancer, metabolic diseases, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cancer, metabolic diseases, hematological diseases, inflammation,... Agent: Banner & Witcoff, Ltd.

20080050315 - Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1): The invention provides a human PRKG1 which is associated with cardiovascular diseases, respiratory diseases, dermatological diseases, endocrinological diseases, metabolic diseases, inflammation, gastroenterological diseases, cancer, hemato-logical diseases, muscle-skeleton-diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular... Agent: Banner & Witcoff, Ltd.

20080050313 - Sulfs as modifiers of the beta-catenin pathway and methods of use: Human SULF genes are identified as modulators of the beta catenin pathway, and thus are therapeutic targets for disorders associated with defective beta catenin function. Methods for identifying modulators of beta catenin, comprising screening for agents that modulate the activity of SULF are provided.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20080050322 - Photostable cosmetic compositions: Photostable cosmetic compositions comprising sunscreens, more particularly to cosmetic compositions comprising dibenzoylmethane sunscreens are provided. It is known that dibenzoylmethane and its derivatives are relatively sensitive to ultraviolet radiation and they decompose rapidly under the effect of sunlight. This decomposition is accelerated in the presence of UV-B sunscreens, especially p-methoxycinnamic... Agent: Unilever Intellectual Property Group

20080050320 - Skin care compositions containing a hydrophobic material and related methods: The invention includes a skin care composition comprising an acrylate polymer; a yield value-increasing polymer; and a non-silicone hydrophobic material. The composition has a yield value of at least about 4. Also included within the scope of the invention are related methods, such as methods of depositing a hydrophobic material... Agent: Colgate-palmolive Company

20080050323 - Sunscreen composition: e

20080050318 - Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines: Disclosed herein is a composition for topical application to skin, comprising, in a physiologically acceptable medium (i) at least one peptide comprising at least one amino acid sequence derived from the amino acid sequence of the protein SNAP 25, and (ii) at least one calcium-channel inhibitor. Further disclosed is the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080050326 - Deodorant composition comprising linalool and dihydromyrcenol: A deodorant composition comprising: a) a fragrance system comprising a fragrance material, and a combination of linalool and dihydromyrcenol, wherein the combination of linalool and dihydromyrcenol is included in the composition in an amount from about 0.2% to about 1% by weight of the composition, and wherein the ratio of... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080050330 - Aqueous hair cosmetic composition: d

20080050331 - Cosmetic composition containing a protease activator: An exfoliation composition comprising a protease activator such as a chestnut extract, at least one exfoliator and a cosmetically acceptable vehicle, and methods of use thereof.... Agent: The Estee Lauder Cos, Inc

20080050332 - Method of skin care and/or treatment using glutaredoxin: Methods for the prevention and treatment of skin damage arising from the exposure to UV radiation, air pollution and other stressors capable of leading to the formation of free radicals, using the small-dithiol protein glutaredoxin in a dermatologically acceptable carrier that can be applied topically are disclosed. Some embodiments may... Agent: Hannah Naomi Sivak

20080050333 - Oil-in-water dispersion: t

20080050329 - Composition for coating keratin fibres comprising a block polymer and fibres: A subject of the invention is a composition for coating keratin fibres comprising, in a cosmetically acceptable medium, a block polymer and fibres. A subject of the invention is also the use of such a composition for obtaining a makeup for the keratin fibres, in particular the eyelashes, which is... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080050334 - Cosmetic composition comprising an extract of emblica officinalis, a hydroxy acid, and an n-substituted aminosulfonic acid, and methods of using same: A cosmetic composition useful for the depigmentation of skin containing an extract of Emblica officinalis, at least one hydroxy acid, and at least one N-substituted aminosulfonic acid having the structural formula (I):... Agent: L'oreal Usa/ Patent Department

20080050336 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080050350 - Method for introducing an exogenous gene into a stem cell: The subject invention relates to a method for introducing an exogenous gene into a stem cell, which comprises introducing the exogenous gene into the stem cell under specific electroporation conditions. The invention also relates to a stem cell stably expressing an exogenous gene, a transgenic animal and a pharmaceutical composition.... Agent: Ladas & Parry

20080050353 - Quality of life for hepatitis c patients with a formulation for administration to the oral mucosa including lactobacillus delbrueckii subsp. bulgaricus and n-acetyl d-glucosamine: Disclosed are quick dissolve tablets, each including Lactobacillus delbrueckii subsp bulgaricus (LBD) and N-acetyl-glucosamine (NAG), as well as excipients, for oral mucosal administration, for improving the quality of life of Hepatitis C patients. Any formulation suitable for oral mucosal administration can be employed for administering the active ingredients in a... Agent: Eric Mirabel

20080050310 - Antibodies and immunoconjugates and uses therefor: Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.... Agent: Genentech, Inc.

20080050311 - Monoclonal antibody hpam4: This invention relates to monovalent and multivalent, monospecific antibodies and to multivalent, multispecific antibodies. One embodiment of these antibodies has one or more identical binding sites where each binding site binds with a target antigen or an epitope on a target antigen. Another embodiment of these antibodies has two or... Agent: Faegre & Benson LLP Patent Docketing

20080050312 - Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents: This invention relates to a method of imaging vesicular monoamine transporters and to labeled compounds and pharmaceutical compositions thereof, and methods of making labeled compounds useful in imaging vesicular monoamine transporters. This invention also relates to compounds, and methods of monitoring progression of a disease related to vesicular monoamine transporters.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080050316 - Molecular imaging of epithelial cells in lymph: Methods and imaging agents for imaging epithelial cancer cells in the lymphatic system are disclosed herein. In an embodiment, an imaging agent for imaging cancer cells in a lymphatic system comprises a fluorescent dye conjugated to one or more antibodies. The antibodies are capable of specific binding to an epithelial... Agent: Conley Rose, P.C. David A. Rose

20080050317 - Oleaginous pharmaceutical and cosmetic foam: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein... Agent: Wilmerhale/boston

20080050319 - Benzylidene-alpha-dicarbonyl compounds as novel uv absorbers: as UV filters in cosmetic formulations, in particular in combination with UV filters from the group consisting of methoxycinnamate derivatives and/or dibenzoylmethane derivatives, with the proviso that R5 is H if R4 is COR, is described.... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20080050321 - Formulations with feruloyl glycerides and methods of preparation: X1 and X2 are the same or different, and at least one of X1 or X2 is a functional group that bonds with the compound comprising at least one UV-absorbing chromophore, and b+f≧2; Y comprises an O, N, or S that is substituted or unsubstituted; each a, b, c, e... Agent: Banner & Witcoff, Ltd.

20080050324 - Method of applying makeup by means of a magnetic composition including at least one differactive pigment: The present invention relates to a method of applying makeup to keratinous substances, in particular the skin, the lips, the nails, or hair, the method comprising the following steps: depositing at least one cosmetic composition on the surface to be made up, the cosmetic composition comprising: bodies that present non-zero... Agent: Oliff & Berridge, PLC

20080050325 - Cosmetic composition with paramagnetic material: Cosmetic composition with paramagnetic material is described. In embodiment(s), a cosmetic composition can include a paramagnetic material in a cosmetic medium where the combination forms a cosmetic application, a lipstick, a lotion, a blush, or other similar application. The paramagnetic material can be included in a quantity sufficient to effectuate... Agent: Sadler, Breen, Morasch & Colby, P.s.

20080050327 - Body care composition with water-soluble abrasive particles: The invention relates to a body care composition, in particular a cosmetic body care composition, more particularly a body cleaning material, comprising solid particles, which are moderately soluble in water. A most preferred embodiment of the present invention is a peeling shampoo.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080050328 - Cosmetic compositions with silicone resin polymers: A cosmetic composition containing a silicone resin polymer comprised of M units in combination with Q or T units or both, wherein the number of M units is greater than the number of Q units or T units or combination thereof, and a method for improving the finish of a... Agent: Julie Blackburn Revlon Consumer Products Corporation

20080050335 - Ophthalmic solutions: Aqueous ophthalmic solutions containing a combination of hyaluronic acid or a pharmaceutically acceptable salt thereof, e.g. sodium hyaluronate, and polyvinyl alcohol are disclosed. These solutions have a synergistic effect on viscosity and provide a statistically significant improvement over the prior art formulations. The solutions are used as artificial tear for... Agent: Innovar, LLC

20080050337 - Method for using calcium-sensitive potassium channel agonist for delivering a medicant to an abnormal brain region and/or a malignant tumor: Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel activator (other than bradykinin or a bradykinin analog), such as NS-1619, EBIO, a... Agent: Davis Wright Tremaine LLP/los Angeles

20080050338 - Stable liquid interferon formulations: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080050339 - Stable liquid interferon formulations: Liquid interferon compositions having a pH between 4.0 and 7.2 are described. The compositions comprise interferon-beta and a stabilizing agent at between about 0.3% and 5% by weight which is an amino acid selected from the group consisting of acidic amino acids, arginine and glycine. If needed, salt is added... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080050340 - Cd40 agonist antibody /type 1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided.... Agent: Hunton & Williams LLP Intellectual Property Department

20080050343 - Adeno-associated virus serotype i nucleic acid sequences, vectors and host cell containing same: The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.... Agent: Howson And Howson

20080050341 - Adoptive immunotherapy with enhanced t lymphocyte survival: The invention provides for compositions, e.g., pharmaceutical compositions, comprising a T lymphocyte, or a population thereof, expressing at least one recombinant polynucleotide encoding a cytokine that enhances T lymphocyte survival during the contraction phase of an immune response. The invention further provides an isolated T lymphocyte, or population thereof, expressing... Agent: Leydig, Voit & Mayer, Ltd.

20080050342 - Genetic inhibition by double-stranded rna: A process is provided of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of... Agent: Morgan Lewis & Bockius LLP

20080050349 - Cell based therapy for the pulmonary system: Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.... Agent: Ridout & Maybee Suite 2400

20080050351 - Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorder: The invention relates to genetic approaches to supply nucleotide sequences encoding modified forms of the native forms of apolipoprotein A-I (ApoA-I): mature ApoA-I, reproApoA-I and proApoA-I; including native ApoA-I modified to contain ApoA-I agonists, peptides which mimic the activity of ApoA-I; ApoA-I superagonists, peptides which exceed the activity of native... Agent: Pfizer Inc.

20080050352 - Pharmaceutical composition comprising botulinum, a non ionic surfactant, sodium chloride and sucrose: The invention relates to a solid or liquid pharmaceutical composition comprising botulinum neurotoxin complex (type A, B, C, D, E, F or G) or high purity botulinum neurotoxin (type A, B, C, D, E, F or G), and a surfactant. In particular the invention relates to a solid or liquid... Agent: Jacobson Holman PLLC

20080050354 - Protecting bioactive food ingredients using microorganisms having reduced metabolizing capacity: The invention concerns a food product containing living microorganisms and bioactive food ingredients of interest, wherein the living microorganisms and the bioactive food ingredients of interest are organized so as to reduce metabolizing of said bioactive ingredients by said living microorganisms. More particularly, the invention concerns the use therefor of... Agent: Foley And Lardner LLP Suite 500

20080050355 - Protection of bioactive food ingredients by means of encapsulation: The invention relates to a food product containing one or more live micro-organisms and at least one bioactive food ingredient of interest, in which the bioactive food ingredient(s) of interest is protected by means of encapsulation in a fat, such as to reduce the metabolisation thereof by the aforementioned live... Agent: Foley And Lardner LLP Suite 500

20080050344 - Biological control of plant diseases: The present invention relates to the use of Ulocladium oudemansii as a biological control agent. Processes and compositions for the biological control of Botrytis species using Ulocladium oudemansii are also provided.... Agent: Jacobson Holman PLLC

20080050345 - Adeno-associated virus serotype i nucleic acid sequences, vectors and host cells containing same: The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.... Agent: Howson And Howson

20080050346 - Elastin producing fibroblast formulations and methods of using the same: The present invention describes therapeutic compositions comprising fibroblasts that have been stimulated to increase expression of extracellular matrix components or elastin, or to produce enhanced elastogenesis or the appearance thereof at a site of administration. The therapeutic fibroblast formulations can be prepared using a variety of elastogenic agents, including digests... Agent: Pepper Hamilton LLP

20080050348 - Method and composition for repairing heart tissue: A method of expanding blood stem cells for the repair of heart tissue and/or function, and compositions resulting from the expansion method in a rotating bioreactor. This invention also relates to a method of TVEMF-expanding blood stem cells for the repair of heart tissue and/or function, and compositions resulting from... Agent: Ladas & Parry LLP

20080050347 - Stem cell therapy for cardiac valvular dysfunction: Disclosed are methods, compounds and compositions useful for treatment of a patient with valvular dysfunction. The invention relates to using stem cells, modified stem cells, derivatives thereof, and agents stimulatory to stem cells in order to substantially ameliorate, and in some cases induce a therapeutic benefit, to a patient suffering... Agent: Knobbe Martens Olson & Bear LLP

20080050356 - Pharmacological vitreolysis: Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are disclosed. TPCDs include, but are not limited... Agent: Wilmerhale/boston

20080050358 - Identification of snps associated with hyperlipidemia, dyslipidemia and defective carbohydrate metabolism: The present invention relates to a nucleic acid molecule comprising a chromosomal region contributing to or indicative of hyperlipidemias and/or dyslipidemias or defective carbohydrate metabolism, wherein said nucleic acid molecule is selected from the group consisting of: (a) a nucleic acid molecule having or comprising the nucleic acid sequence of... Agent: Birch Stewart Kolasch & Birch

20080050357 - Systems and methods for antibody engineering: Methods, computer systems, and computer program products for antibody engineering. A variant set for an antibody of interest is constructed by identifying, using a plurality of roles, a plurality of positions in the antibody of interest and, for each respective position in the plurality of positions, substitutions for the respective... Agent: Jones Day

20080050360 - Method of treating a pathological syndrome and a pharmaceutical agent: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms... Agent: Houston Eliseeva LLP - Ru

20080050362 - Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells: The invention provides compositions comprising one or more isolated factors from a microenvironment of human embryonic stem cells (hESCs), including, but not limited to, Lefty and inhibitors of Nodal. The invention also provides methods of utilizing factors derived from human embryonic stem cells (hESC) and their microenvironment to treat and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20080050363 - Novel nucleic acid molecules encoding opioid growth factor receptors: This invention relates to novel nucleic acid molecules coding for opioid growth factor receptors. In particular, the present invention provides isolated nucleic acid molecules coding for human and rat OGF receptors. Antisense molecules, expression vectors and host cells, isolated proteins encoded by such nucleic acid molecules, antibodies directed against such... Agent: Scully Scott Murphy & Presser, PC

20080050359 - Production of anti-self antibodies from antibody segment repertoires and displayed on phage: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface... Agent: Howrey LLP

20080050361 - Staphylococcus aureas specific anti-infectives: The present invention provides novel anti-infectives that act on Staphylococcus aureus (S. aureus) iron-regulated surface determinants, IsdA, IsdB, IsdC, IsdH (or HarA).... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080050364 - Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist: A method is provided for reducing the occurrence of fever, headache, nausea and/or vomiting associated with administration of a therapeutic compound to a mammal in need thereof, comprising administering to the mammal a first conditioning dose of a non-target cell depleting compound which binds to a cell surface receptor on... Agent: Genentech, Inc.

20080050365 - Anti-hiv antibody: The present invention aims at providing a high affinity anti-HIV antibody. According to the present invention, there are provided an antibody or a fragment thereof that binds to the gp12 glycoprotein of HIV and has a dissociation constant (KD) value of 1.0×10−9 (M) or less; a pharmaceutical composition comprising the... Agent: Birch Stewart Kolasch & Birch

20080050368 - Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith: The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering... Agent: Foley Hoag, LLP/wyeth Patent Group, (w/wys)

20080050375 - Binding compositions: related reagents: TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for thereaputic purpose are also provided.... Agent: Eli Lilly & Company

20080050371 - Cd16a binding proteins and use for the treatment of immune disorders: CD16A binding proteins useful for the reduction of a deleterious immune response asre described. In one aspect, humanized anti-cd16A antibodies, optionally lacking effector function, are used for the treatment of immune disorders such as idiopathic thrombocytopenic purpura and autoimme hemolytic anemia.... Agent: King & Spalding

20080050367 - Humanized antibodies that recognize beta amyloid peptide: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.... Agent: Lahive & Cockfield, LLP

20080050372 - Inhibition of alpha-2 hs glycoprotein (ahsg/fetuin) in obesity and insulin control of glucose homeostasis: α2-Heremans Schmid Glycoprotein (AHSG) inhibits insulin-induced autophosphorylation of the insulin receptor (IR) and IR-tyroskine kinase (TK) activity; genetic ablation of the Ahsg gene enhances insulin signal transduction and increase whole-body insulin sensitivity. Therefor, AHSG and its gene(s) are useful targets for agents that inhibit the development or progression of Type... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080050366 - Neutralizing antibodies and methods of use thereof: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins,... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080050374 - Novel antigen-binding polypeptides and their uses: Novel antigen-binding polypeptides (ABP) and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20080050370 - Stabilized polypeptide compositions: The invention is based, at least in part, on the development of stabilized binding molecules that consist of or comprise a stabilized scFv and methods for making such stabilized molecules.... Agent: Lahive & Cockfield, LLP

20080050369 - Therapeutic applications of t-bam (cd40l) technology to treat diseases involving smooth muscle cells: Activation of smooth muscle cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the smooth muscle cells with an anti-T-BAM (CD40L) antibody capable of inhibiting the interactions between CD40 ligand and the CD40-bearing smooth muscle cells, in an amount effective to inhibit activation of the... Agent: Ropes & Gray LLP Patent Docketing 39/361

20080050373 - Treatment with anti-erbb2 antibodies: The present invention concerns the treatment of cancer with anti-ErbB2 antibodies.... Agent: Genentech, Inc.

20080050376 - Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells: The present invention discloses antibodies, antigen binding fragments, peptides and peptidomimetics immunoreactive with provasopressin and compositions thereof, methods of phenotyping tissue samples, methods of treating cancer, and kits for phenotyping test biopsy samples and bodily fluids for breast cancer, small cell lung cancer, ductal carcinoma in situ, and atypical ductal... Agent: Ropes & Gray LLP Patent Docketing 39/41

20080050377 - Compositions and methods relating to stop-1: The present invention provides novel polypeptides, antibodies, antagonists, agonists, potentiators, nucleic acid molecules, compositions and methods relating to the STOP-1 polypeptide that are useful for treating and preventing diseases and for medical diagnosis and research. The present invention also provides consensus sequences and specific sequences for antibodies that specifically bind... Agent: Genentech, Inc.

20080050378 - Method for diagnosing non-small cell lung cancer: Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1.... Agent: Townsend And Townsend And Crew, LLP

20080050379 - Cancer gene determination and therapeutic screening using signature gene sets: Processes for assaying potential antitumor agents based on their modulation of the expression of specified genes, or sets, of suspected cancer cell genes are disclosed, along with methods for diagnosing cancerous, or potentially cancerous, conditions as a result of the expression, or patterns of expression, of such genes, or sets... Agent: Alan J. Grant, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20080050380 - Glycoprotein vi and uses thereof: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20080050381 - Antihuman baff antibody: An antibody against a peptide having an amino acid sequence AVQGPEETVT QDC (expressed in single letter amino acid code) corresponding to the 134- to 146-positions in human BAFF (B cell activating factor belonging to the TNF family) protein which is preferably a monoclonal antibody; a method of producing the above... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080050382 - Granulysin and uses thereof: Disclosed are uses of granulysin in methods of diagnosing or treating autoimmune disorders.... Agent: Occhiuti Rohlicek & Tsao, LLP

20080050383 - Immunotherapy for clearing pathological tau conformers: The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed... Agent: Nixon Peabody LLP - Patent Group

20080050386 - Novel proteins, gene encoding the same and method of utilization thereof: The present invention provides, as a gene encoding an antigen recognized by G-CSF-inducing antibodies, a gene encoding: (a) a protein having the amino acid sequence listed as SEQ ID NO:2 of the Sequence Listing; (b) a protein having the amino acid sequence listed as SEQ ID NO:2 of the Sequence... Agent: Birch Stewart Kolasch & Birch

20080050384 - Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors: In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080050385 - Tumor therapy with an anti-vegf antibody: The present invention provides a method of treating a patient suffering from relapsed HER2 positive cancer with an anti-VEGF antibody during or after treatment with an anti-HER2 antibody. The invention also provides a kit comprising an anti-VEGF antibody.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20080050387 - Non-androgen dependent roles for androgen receptor and non-androgen related inhibitors of androgen receptor: Disclosed are compositions and methods for modulating AR activity, such as non-androgen dependent AR activity. Also disclosed are compositions and methods for diagnosing beast cancer and for inhibiting breast cancer growth. In addition, disclosed are methods for identifying molecules that inhibit AR in non-androgen dependent ways.... Agent: Needle & Rosenberg, P.C.

20080050388 - Humanized collagen antibodies and related methods: The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic... Agent: Wilson Sonsini Goodrich & Rosati

20080050389 - Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots: Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.... Agent: Howson And Howson

20080050390 - Administration of gamma globulins to treat metastatic melanoma: This invention relates to cancer therapy and in particular to the administration of gamma globulins to inhibit both primary tumor and metastasis and augment treatment of primary cancerous tumors. In accordance with this invention, the treatment of various cancerous diseases is accomplished by administering a preparation containing intact gamma globulins... Agent: Pearl Cohen Zedek Latzer, LLP

20080050391 - Method for treating autoimmune diseases with antibodies: A method for treating autoimmune diseases in a mammal which method comprises administering to the mammal an effective amount of at least one antibody specific for a soluble antigen is provided. Furthermore, a novel mechanism of action has been established in accordance with the present invention for antibody-based treatment regimes... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080050392 - Method of treating a pathological syndrome and a pharmaceutical agent: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms... Agent: Houston Eliseeva LLP - Ru

20080050393 - Novel nucleic acids and polypeptides: The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids and uses thereof.... Agent: Nuvelo, Inc

20080050394 - System and device for medically treating an individual: A system for medically treating/vaccinating an individual comprising a first syringe, containing an anticoagulant material therein, for drawing a sample of blood from the individual. A centrifuge means for centrifuging the sample of blood contained within the first syringe to obtain a buffy coat. A second syringe comprising a second... Agent: James Ray & Associates

20080050395 - Methods for preparing and delivering adjuvant compositions: Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin and a polymer. The polymer is preferably polyacrylic acid-based and the delivery method involves administering a vaccine, including an antigen and the adjuvant, to a mucosal surface.... Agent: Stites & Harbison PLLC

20080050396 - Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients: The present invention relates to proteins belonging to the Bcl-2 family and peptides fragments thereof for use in pharmaceutical compositions. The disclosed proteins and peptide fragments are in particularly useful in vaccine compositions for treatment of cancer. The invention furthermore relates to methods of treatment using said compositions. It is... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080050397 - Multiple antigenic agents and methods for using the same: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections. The multiple antigenic agents of the invention contain at least one of a B cell determinant, a T cell determinant, or a targeting molecule attached to a core peptide composed of Lys-Gly... Agent: Licata & Tyrrell P.C.

20080050398 - Composition comprising beta-defensin 2: The invention relates to compositions comprising at least one peptide with a structure or structural pattern of β-defensin 2 and/or its derivatives, especially human β-defensin 2. The compositions are selected in particular from cosmetic and/or pharmaceutical compositions, cleaning and/or washing agents, water-treatment agents and cooling lubricants. The invention also relates... Agent: Woodcock Washburn LLP

20080050399 - Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins: This document describes compositions and methods for inducing an immune response (e.g., a cellular response such as a cell-mediated cytolytic immune response) to a human papillomavirus (HPV) antigen, which can be displayed by HPV or exhibited by infected cells (e.g., cells from cervical and other tumors). The HPV protein can... Agent: Fish & Richardson PC

20080050400 - Method of accelerating the growth and development of trees and shrubs via enhanced root development: A method of developing seedlings includes germinating the seeds and air pruning the seedlings to a depth of about 3 inches.... Agent: B. Jefferson Boggs Bingham Mccutchen, LLP

20080050401 - Rescue of influenza virus: The invention relates to the field of influenza vaccine production. Influenza vaccines have been produced in embryonated hens' eggs for over 50 years, but recently there have been considerable efforts to develop cell culture systems for vaccine production. The invention provides a nucleic acid comprising an influenza gene segment and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080050402 - Attenuated influenza ns1 variants: Attenuated influenza virus variants comprising substitutions in NS1 that interfere with viral replication and phosphatidylinositol 3-kinase activation are described. NS1 variant polypeptides, polynucleotides encoding NS1 variant polypeptides, a reverse genetics system for producing attenuated influenza virus NS1 variants, immunogenic compositions comprising live attenuated influenza virus NS1 variants, methods of stimulating... Agent: Robins & Pasternak

20080050403 - Production of viruses, viral isolates and vaccines: The present invention discloses methods for producing and/or propagating virus particles, such as influenza virus particles, that are present in a virus isolate obtained from an infected subject by contacting a host cell with a virus particle and culturing the cell under conditions conducive to propagation of the virus particle.... Agent: Trask Britt

20080050404 - Pressure sore treatment: Methods for treating a pressure sore or for preventing development of a pressure sore by local administration of a Clostridial toxin, such as a botulinum neurotoxin, to a pressure sore or to a pressure point, or to the vicinity thereof.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20080050405 - Ringworm vaccine: A ringworm vaccine is disclosed comprising antigen isolated from at least one dermatophyte and a suitable carrier. The “antigen” can include a single antigen from a dermatophyte or a plurality of antigens as long as at least one antigen is included which will produce a sufficient immune response to confer... Agent: Crowell & Moring LLP Intellectual Property Group

20080050406 - Modified mite allergen and pharmaceutical uses thereof: The present invention provides a modified Dermatophagoides pteronyssinus allergen Der p 5 protein which has ability to inhibit IgE binding when exposed against to the antigen. A method for treating allergy comprising administrating a therapeutically effective dose of the modified D. pteronyssinus allergen Der p 5 protein to a subject... Agent: Banner & Witcoff, Ltd.

20080050408 - Dental whitening compositions: A whitening system has a de-sensitizing effect as well as re-mineralizing capability. The system may be a one-component or a two-component composition. The system may also be an unfoamed, a foamed or a foamable composition. For a one-component system, a sparingly soluble calcium phosphate salt may be in dry particle... Agent: Discus Dental Impressions, Inc.

20080050407 - Oral care products comprising buffer systems for improved mineralization/remineralization benefits: Oral products for the improved mineralization/remineralization of teeth are provided. In an embodiment, the present disclosure provides an oral product comprising a calcium salt, a phosphate salt, a sodium salt and a potassium salt. For example, the molar ratio of the sodium salt to the potassium salt ranges from about... Agent: Bell, Boyd & Lloyd LLP

20080050409 - Water based clear sunscreen and insect repellent composition: A clear, water based, homogeneous insect repellent sunscreen composition, comprising an oil soluble hydrophobic sunscreen component, an amido insect repellent component, an alcohol component, and water.... Agent: Charles J. Zeller, Esq. Avon Products Inc.

20080050410 - Self-decontaminating surface coatings and articles prepared therefrom: The present invention is directed toward a self-decontaminating surface coating, which when cured has a partially hydrophobic surface. The coating comprises a polymeric coating resin which, when cured, is hydrophilic. The coating also comprises a biocide, a germinating agent, and a hydrophobic micro/nano particulate material. The coating is suitable for... Agent: Joy L Bryant, P.C.

20080050411 - Texas game draw: The present invention is a game attractant comprised of a mixture of rice bran, wheat bran and dried molasses to attract the attention of ungulates and avian fauna. By the incorporation of these three ingredients, the nutritional and vitamin value is elevated above the natural diet of the fauna. Therefore... Agent: Jon David Rudo

20080050412 - Antimicrobial implant: A method of building an orthopedic implant including the steps of mixing a powder having antimicrobial properties with a biocompatible powder to form a mixture. Next, the mixture is deposited on top of a substrate. The substrate may be part of the finished product or only a work platform. The... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20080050413 - Medical stent provided with a combination of melatonin and paclitaxel: A stent is provided with a composition which includes melatonin and paclitaxel for use in treating smooth muscle cell proliferation, such as stenosis and preventing restenosis in vascular vessels.... Agent: Knobbe Martens Olson & Bear LLP

20080050415 - Polymeric/ceramic composite materials for use in medical devices: According to an aspect of the invention, implantable or insertable medical devices are provided, which contain one or more composite regions. These composite regions, in turn, contain (a) a polymeric component comprising a vinyl aromatic polymer and (b) a ceramic component comprising a metal or semi-metal oxide.... Agent: Mayer & Williams PC

20080050416 - Bone delivery device: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.... Agent: Searete LLC Clarence T. Tegreene

20080050414 - Methods for treating or preventing restenosis and other vascular proliferative disorders: Described herein is the use of ribonucleotide reductase inhibitors in the prevention or treatment of restenosis and other vascular proliferative disorders.... Agent: Needle & Rosenberg, P.C.

20080050417 - Alginate coated, collagen matrix cellular device, preparative methods, and uses thereof: The present invention is directed to cellular devices comprising a collagen matrix, cell layer, and gelled alginate layer, processes for producing the devices, methods of implanting the devices, and methods of treatment thereof.... Agent: Patent Administrator Fmc Corporation

20080050418 - Medical devices for the release of therapeutic agents: According to one aspect of the invention, medical devices are provided which contain the following: (a) an interior region that contains at least one degradation promoting agent and (b) an exterior region disposed over the interior region that contains at least one biodegradable polymer and at least one therapeutic agent.... Agent: Mayer & Williams PC

20080050419 - Epoxy-containing poly(ester amides) and method of use: The invention provides aliphatic epoxy-containing PEA polymer compositions with film-forming properties. The aliphatic epoxy di-acids used in the invention PEA compositions include non-toxic fatty aliphatic epoxy homologs. A second, C-protected L-lysine-based monomer can be introduced into the polymer to provide additional chain flexibility. The invention PEA polymer compositions are useful... Agent: Dla Piper US LLP

20080050420 - Methods for reducing neovascularization or edema: Methods for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.... Agent: Allergan, Inc.

20080050421 - Methods for reducing neovascularization or edema: Drug delivery devices for reducing or preventing neovascularization or edema in the eye by implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.... Agent: Allergan, Inc.

20080050422 - Method of administering a film product containing a drug: The invention relates to a fast-dissolving film product containing at least one drug; and a water soluble polymer composition. The invention further relates to methods of administering the film product. The method includes administering the film to the oral cavity of a subject in need of the drug; and administering... Agent: Hoffmann & Baron, LLP

20080050423 - Biopolymer-bioengineered cell sheet construct: The present invention discloses a biopolymer-bioengineered human corneal endothelial cell (HCEC) sheet construct for reconstructing corneal endothelium in a patient. The construct includes a biopolymer carrier which is bioresorable and deformable; and a bioengineered cell sheet comprising a monolayer of interconnected HCECs with substantially uniform orientation, wherein the bioengineered cell... Agent: Bacon & Thomas, PLLC

20080050424 - Transdermal therapeutic system for treating parkinsonism: A transdermal therapeutic system (TTS) comprises a silicone-based polymer adhesive system having distributed therein (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol free base in an amount of about 5% to 40% by weight. The adhesive system comprises a silicone adhesive and an additive having increased solubility for the active substance, in an amount effective to increase... Agent: Harness, Dickey, & Pierce, P.l.c

20080050425 - Combination chemotherapy comprising 5-fluorouracil or a derivative thereof and a liposomal platinum complex: The present invention relates to methods for treating cancer comprising administering a combination of 5-fluorouracil or a derivative thereof and a liposomal platinum complex. Pharmaceutical compositions comprising 5-fluorouracil or a derivative thereof and a liposomal platinum complex, and kits comprising unit doses of 5-fluorouracil or a derivative thereof and liposomal... Agent: Jones Day

20080050426 - Method for preparing extract from wild ginseng showing anticancer activity and the composition comprising the same: The present invention relates to a method for preparing purified extract from wild ginseng showing anticancer activity such as inhibitory of cancer cell adherence, inhibitory of cancer cell metastasis and immunostimulating effect and a composition comprising the same prepared by inventive method. The composition have potent anticancer activity, therefore, it... Agent: Kirk Hahn

20080050427 - Analgesic combination of tramadol and meloxicam: Disclosed is a pharmaceutical composition, comprising a combination of a dose of meloxicam or a pharmaceutically acceptable salt thereof and a dose of oxycodone or a pharmaceutically acceptable salt thereof, said combination in an amount sufficient to provide an analgesic effect in a human patient. Also disclosed is a method... Agent: Davidson, Davidson & Kappel, LLC

20080050428 - Oral pharmaceutical preparation comprising a proton pump antagonist and a basic excipient: The invention relates to novel extended release dosage forms for reversible proton pump antagonists comprising a basic excipient.... Agent: Nath & Associates PLLC

20080050429 - Low flush niacin formulation: The invention relates to an extended-release matrix formulation capable of being directly compressed into tablets comprising niacin, a release-retarding agent, and other excipients. The resulting tablets of the invention demonstrate favorable release characteristics and a reduction in the severity, duration and incidences of cutaneous flushing commonly associated with niacin treatment.... Agent: Kos Pharmaceuticals, Inc.

20080050430 - Pharmaceutical compositions and methods for improved bacterial eradication: A process for treating a bacterial infection with an antibiotic, comprising: administering to a patient with a bacterial infection a product that includes a modified release dosage form containing an antibiotic, said product being administered once-a-day in a dosage and for a number of days that provides a Total T>MIC... Agent: Raymond E. Stauffer, Esq. C/o Carella, Byrne, Bain, Gilfillan, Cecchi,

20080050431 - Sustained release formulations of oxymorphone: Sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of oxymorphone or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.... Agent: Wilmerhale/boston

20080050432 - Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors: The present invention relates to a combined pharmaceutical formulation, which is such designed that the release of each ingredient may be controlled to a predetermined release rate by applying the principle of the so-called chronotherapy, where drugs are administered in such a way that the activities of the drugs are... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20080050433 - Water-soluble films for releasing active substances: The invention relates to a water-soluble film for releasing active substances, particularly plant protection products and plant growth promoting substances. The water-soluble film can be defined with regard to its dimensions so that the content of the active substance can be exactly pre-dosed in such a defined film section. The... Agent: Frommer Lawrence & Haug

20080050434 - Novel composition for topical delivery: Pharmaceutical composition for topical administration comprising of at least one active ingredient, its salts, esters, hydrates or derivatives; a gelator system consisting of a fiend of surfactants, a solvent system comprising at least one oily component; an aqueous phase; optionally containing one or more stabilizing agent; and other pharmaceutically acceptable... Agent: Ladas & Parry

20080050435 - Temperature sensitive polymers: The present invention relates to compositions comprising polymers whose solubility characteristics can be changed by incubation and particularly ploy (hydroxyalkyl (meth) acrylamide mono/di-lactate) interpolymers. Another aspect of this invention is the application of such temperature sensitive polymers as release systems of biologically active compounds. The polymers of the present invention... Agent: Morrison & Foerster LLP

20080050436 - Methods and compounds for obliteration of vessels: A minimally invasive method that allows for complete obliteration of the affected vessels without scarring or any of the other undesirable complications of conventional or foam sclerotherapy. More particularly, the present invention relates to a method for using a non-foaming thickener to reduce dilution and diffusion of the sclerosant in... Agent: Jack Chu

20080050437 - Modified release pharmaceutical formulation: A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R1 represents C1-2 alkyl substituted by one or more fluoro substituents; R2 represents hydrogen, hydroxy, methoxy or ethoxy, and n represents 0, 1 or 2; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable... Agent: Morgan Lewis & Bockius LLP

20080050438 - Dry compositions: A dry composition of the present invention comprises at least one of active ingredients selected from the group consisting of pharmacologically active proteins and pharmacologically active polypeptides and as a stabilizer at least one of hydrophobic stabilizers selected from the group consisting of hydrophobic amino acids, hydrophobic dipeptides and hydrophobic... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080050439 - Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans,... Agent: Peters Verny , L.L.P.

20080050442 - Nasal pharmaceutical formulations and methods of using the same: Nasal pharmaceutical formulations comprising a drug substance having a specific particle size distribution profile are disclosed herein. Such profile provides increased bioavailability, increased efficacy or prolonged therapeutic effect of the drug substance when administered intranasally. The formulations of the present invention may comprise one or more corticosteroids having a specific... Agent: Alston & Bird LLP

20080050440 - Plant epidemic prevention agent, plant epidemic prevention method, plant epidemic prevention system, plant, and plant cultivation method: The present invention provides a plant epidemic prevention agent that allows for easily and efficiently decomposing and eliminating pathogenic germs that cause plant epidemic and effectively suppressing plant disease caused by the pathogenic germs and making diseased plants recover from the disease without adversely affecting the human body and allows... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20080050441 - Process for the preparation of solid sterile active pharmaceutical ingredient: The present invention provides a method of preparing a packed sterile solid active pharmaceutical ingredient, in particular sterile steroids such as a glucocorticosteroid acid.... Agent: Kenyon & Kenyon LLP

20080050445 - Niosome-hydrogel drug delivery: Taught herein is a drug-delivery system that includes encapsulating a therapeutic drug in a nanoparticle vesicle that is then embedded into a hydrogel network. The system allows for enhanced, two-fold control over the release rate of the drug. This technology will be particularly advantageous in treating malignant cancer cells such... Agent: Smith Hopen, Pa

20080050448 - Antimicrobial conjugates: The present invention presents a metallic nanoparticle-ligand-photosensitiser conjugate, a method of making such conjugate, and a method of using such mixture for killing or preventing the growth of microbes.... Agent: Dobrusin & Thennisch PC

20080050443 - Fast release composition including melt granules of a moisture sensitive drug and process for manufacturing thereof: Solid oral dosage forms that include melt granules of a moisture-sensitive therapeutic compound and a hydrophobic melt component. The melt granules better protect the therapeutic compound from hydrolytic degradation. Such solid oral dosage forms also possess immediate-release characteristics rather than that associated with extended-release or controlled-release drug products.... Agent: Novartis Corporate Intellectual Property

20080050446 - Fast release dosage forms for antibiotics: A multiparticulate, pharmaceutical dosage form containing at least one antibiotic which is sparingly wettable with aqueous media or sparingly soluble in aqueous media and a combination of carrageenan and tricalcium phosphate and optionally sucrose ester. Also, an administration system having this dosage form arranged in a drinking straw with at... Agent: Crowell & Moring LLP Intellectual Property Group

20080050444 - Pharmaceutical compositions of ilaparazole: The present invention relates to pharmaceutical compositions comprising solid particles of an active ingredient that have a particle size of from about 0.1 micron to about 100 microns.... Agent: Dykema Gossett PLLC

20080050447 - Residual solvent extraction method and microparticles produced thereby: Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a... Agent: Covington & Burling, LLP Attn: Patent Docketing

20080050449 - Controlled release formulation of tolterodine: The invention encompasses stable multiparticulate pharmaceutical compositions of tolterodine having at least one pharmaceutically acceptable excipient and at least two populations of multiparticulates each population having tolterodine or a salt thereof and the ratio of the populations is from 90:10 to 10:90 by weight, wherein after storage for 1 month... Agent: Kenyon & Kenyon LLP

20080050450 - Active agent formulations, methods of making, and methods of use: Active agent compositions comprising active agent particles having an effective average particle size of less than 2000 nm, wherein the compositions comprise a particle sequestrant are disclosed. Compositions having an effective average particle size of less than 2000 nm, wherein the compositions comprise no added surfactants, phospholipids, or combinations thereof,... Agent: Cantor Colburn, LLP

20080050451 - Methods for assessing dehydration and shock, assays and kits for the methods: The present invention is in the medical and consumer arenas. The invention presents the use of a salivary amylase assay to diagnose, quantify, and monitor the hydration status, the onset and progress of shock in an animal that produces salivary amylase, such as a human. The assay tests the saliva... Agent: Wean Khing Wong Attorney At Law

20080050452 - Metal-containing formulations and methods of use: Metal-containing materials, as well as their preparation, formulations, and use are disclosed.... Agent: Fish & Richardson PC

20080050453 - Trace elements: The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium and which comprises a concentration of the metal(s) of at least 60 mg/ml. The solution further comprises at least one compound selected from the group comprising... Agent: Stites & Harbison PLLC

20080050454 - Compositions and methods for nutrition supplementation: The present invention relates to compositions that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment comprising vitamin A, beta carotene, B-complex vitamins, vitamin C, vitamin D3, vitamin E, iron, magnesium and zinc, and methods for using these compositions for nutritional supplementation in... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080050455 - Equine gastric ulcer therapy compositions and equine ulcer management method: An equine gastric ulcer therapy composition comprises a pre-packaged, dry feed supplement comprising effective amounts of chamomile tea and an effective amount of slippery elm with effective amounts of apples and a natural sweetener. An alternative composition comprises a pour-able aqueous solution of an effective amount of chamomile tea and... Agent: Blynn L. Shideler The Blk Law Group

20080050456 - Intramammary formulations: The present invention relates to intramammary formulations, as well as methods of treating an intra-mammary infection in a lactating non-human animal and preventing re-infection by internal administration of the formulations. The formulations include a combination of penicillin, aloe vera and Centella asiatica extract.... Agent: Knobbe Martens Olson & Bear LLP

20080050457 - Ginkgo biloba extract and method for producing the same: The invention relates to a Ginkgo biloba extract and to a method for producing the same. The invention especially relates to a Ginkgo extract having an increased content in desired, pharmaceutically effective active ingredients and to a method which uses water as the extractant.... Agent: Schweitzer Cornman Gross & Bondell LLP

20080050459 - Cosmetic lightening preparation: A cosmetic preparation comprises an effective amount of Phyllanthus Embilca fruit extract and at least one oligopeptide such as Oligopeptide-4 and Oligopepticje-5 (pro-Elastin oligopeptide) The cosmetic preparation may further comprise Licorice extract, and Alpha-arbutin. It has surprisingly been found that this cosmetic preparation displays a beneficial synergistic effect for the... Agent: Cohen Pontani Lieberman & Pavane LLP

20080050458 - Lupin total extract consisting of a lupin sugar extract and a lupin peptide extract, method for the production and use thereof: The invention relates to a composition comprising a lupin total extract consisting of a lupin sugar extract, comprising at least 50% galactooligosaccharides by weight, in relation to the weight of dry matter, and a lupin peptide extract. The composition can also contain a chromane derivative or a chromene derivative. The... Agent: Foley And Lardner LLP Suite 500

20080050461 - Nanoparticulate compositions of angiogenesis inhibitors: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner LLP

20080050460 - Uses of lectin-conotoxin: Provided herein are novel onco-fetal carbohydrate motifs present in adenocarcinoma cells. This novel carbohydrate motif is preferentially recognized by tomato fruit lectin-conotoxin. Also provided are methods for inhibiting proliferation and growth of cancer cells and for treating pathophysiological conditions, e.g., cancer, chronic pain, inflammation and/or a microbial infection, by contacting... Agent: Benjamin Aaron Adler Adler & Associates

20080044349 - Therapeutic and diagnostic applications of perlecan domain i splice variants: A method of producing antibodies comprising the step of encoding a peptide sequence from a Domain I perlecan splice variant, wherein the peptide sequence is used to produce anti-peptide antibodies.... Agent: Proteotech, Inc.

20080044351 - Method and procedure to detect oral tissues with high-risk molecular profiles: A diagnostic method for detecting high risk oral tissue which due to chromosome allelic loss and may have developed or will potentially develop into carcinoma in situ and carcinoma by using a staining agent. A set of questionnaire that identifies high-risk individual and high-risk lesions and helps to reduce false... Agent: Xin Ye

20080044350 - Optical imaging contrast agents for imaging lung cancer: The invention provides contrast agents for optical imaging of prostate cancer in patients. The contrast agents may be used in diagnosis of prostate cancer, for follow up of progress in disease development, for follow up of treatment of prostate cancer and for surgical guidance. Further, the invention provides methods for... Agent: Ge Healthcare, Inc.

20080044362 - Cosmetic composition comprising block copolymer templated metal oxide particles: Disclosed are cosmetic compositions containing a metal, a polymer having a non-functional domain and a functional domain having a plurality of functional groups that interact with the metal, and a cosmetically acceptable carrier. Also disclosed are methods and systems for applying the composition to keratinous substrates, whereby aggregates of the... Agent: L'oreal Usa/ Patent Department

20080044369 - Hair care composition: A hair care solution configured to reduce volume and size of the product includes a hydrophilic polymer, and a hair care ingredient encapsulated in the water-absorbent polymer. Accordingly, the encapsulated hair care ingredient is released for use when the hydrophilic polymer is activated with water.... Agent: Rader, Fishman & Grauer PLLC

20080044371 - Taste-masked composition of cationic exchange resin: The present invention provides a taste-masked composition containing an active compound. The composition is taste-masked by employing a loaded polymeric matrix which is produced by incorporating or complexing the active compound on a polymeric matrix having ionic functional groups and removing unbound active compounds from the polymeric matrix.... Agent: Novartis Corporate Intellectual Property

20080044376 - Cytokine design: The present invention relates to novel methods for the design of proteins, in particular, cytokines. These methods allow the stabilisation of such cytokines, as well as modification of their selectivity/specificity for their cognate receptors. The invention also relates to various modified proteins that have been designed by the methods of... Agent: Woodcock Washburn LLP

20080044379 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080044380 - Hepatitis c virus inhibitors: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Agent: Louis J. Wille Bristol-myers Squibb Company

20080044377 - Poxvirus vector encoding retrovirus (eg hiv) and cytokine: In one embodiment, there is provided a method for treatment or prophylaxis of one or more symptoms of a retrovirus infection such as HIV infection, comprising the administration of poxvirus vector encoding a retrovirus antigen and a cytokine, or a functional homolog, derivative part or analog thereof, in conjunction with... Agent: Scully, Scott, Murphy & Presser, P.C.

20080044392 - Isolation of stem cell-like cells and use thereof: The present invention relates to isolated stem cell-like cells and a method of isolation. The invention also relates to a media composition for producing primary cell cultures comprising predominantly tissue-specific progenitor cells or stem cell-like cells. In particular, the present invention relates to an isolated mesenchymal connective tissue-derived stem cell.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080044396 - Method of raising livestock: The present invention provides a method of raising livestock, which can improve an efficiency of propagating or rearing without using a drug such as an antibiotic or a disinfectant. The method uses a lactic acid bacterium (such as Enterococcus faecium or Lactobacillus fermentum) proliferated and cultured in a medium containing... Agent: Smith, Gambrell & Russell

20080044397 - Compositions to reduce or prevent skin cancer: Compositions of human proteins, methods and regimens for reducing the occurrence and growth of skin cancer, including melanoma, are provided. The methods include steps of administering topically on the skin tumor or a skin cancer-free area of compositions containing therapeutically effective amounts of human alkaline phosphatase, transferrin and α1-antitrypsin. In... Agent: Faegre & Benson LLP Patent Docketing

20080044348 - Tetanus toxin fragment c based imaging agents and methods, and confocal microscopy dataset processes: Methods for purifying Tetanus Toxin Fragment C comprising obtaining a supernatant comprising soluble Tetanus Toxin Fragment C and purifying Tetanus Toxin Fragment C under native conditions to obtain a substantially purified Tetanus Toxin Fragment C. Imaging agents comprising a Tetanus Toxin Fragment C and a reporter, and methods thereof. Methods... Agent: Baker Botts, LLP

20080044352 - Compositions and methods for lipoprotein uptake assays: Provided herein are compositions and methods for lipoprotein uptake assay. These compositions and methods may be used for lipoprotein uptake assays, including high-throughput assays. The disclosed compositions and method may further be used to characterize the activity agents that inhibit or stimulate lipoprotein uptake.... Agent: General Electric Company Global Research

20080044356 - Assemblies of oligomeric amyloid beta protein and uses thereof: The present invention provides assemblies of oligomeric amyloid beta protein and uses thereof.... Agent: Mueting, Raasch & Gebhardt, P.A.

20080044353 - Combination therapy for weight management: Compositions and methods are provided for weight management. The compositions generally comprise a MCHR antagonist, either in combination with a CB1 antagonist or formulated for coadministration with a CB1 antagonist. Certain methods involve coadministering a MCHR antagonist and a CB1 antagonist to a patient.... Agent: Cantor Colburn, LLP

20080044354 - Compounds containing a n-heteroaryl moiety linked to fused ring moieties for the inhibition of nad(p)h oxidases and platelet activation: The invention relates to compounds containing a N-heteroaryl moiety, which is linked via oxygen, sulfur or nitrogen, or via a methylene bridge and oxygen, sulfur or nitrogen to a fused ring moiety, in particular to the 1,2,3-triazolo[4,5d]pyrimidine-7-yl radical. The invention also relates to a process for the preparation of said... Agent: Thelen Reid Brown Raysman & Steiner LLP

20080044357 - Methods and systems for high throughput research of ionic liquids: The present invention provides a method and a system for processing a plurality of ILs, wherein the processing comprises one or more selected from the group of synthesis, separation, detection, purification, determination and so on, and the methods and systems for processing applies high throughput technique. By using the high... Agent: Perkins Coie LLP

20080044355 - Modulators of atp-binding cassette transporters: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.... Agent: Jonathan P. O'brien

20080044358 - Methods for lymph system imaging: Methods and contrast agents for imaging the lymph system are provided. The methods allow the diagnosis and staging of diseases of the lymph system, such as cancer and infections.... Agent: Fish & Richardson P.C.

20080044359 - Cell permeable probe: A cell permeable probe is disclosed. The cell permeable probe includes a cell membrane translocating element, which facilitates transport of the probe into the intracellular component of a cell. The cell permeable probe may also include a plurality of binding moieties for a disease specific marker and a contrast agent.... Agent: Mcdonald Hopkins LLC Suite 2100

20080044360 - Methods of collagen imaging: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.... Agent: Fish & Richardson P.C.

20080044361 - Hfa suspension formulations containing an anticholinergic: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1α,2β,4β,5α,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080044363 - Therapeutic dental composition: A solid or semi-solid oral therapeutic dental composition comprising a therapeutic agent dispersed in a water-insoluble or water-resistant carrier. The dental composition may be in the form of a crayon or dispensed from a delivery device such as a pen or the like.... Agent: Discus Dental Impressions, Inc.

20080044364 - Flavonoid complexes: where R1 to R10 may be identical or different and are selected from H, OR11, straight-chain or branched C1- to C20-alkyl groups or hydroxyalkyl groups, straight-chain or branched C3- to C20-alkenyl groups and/or C3- to C12-cycloalkenyl groups, where the rings may each also be bridged by —(CH2)n— groups, where n=1... Agent: Millen, White, Zelano & Branigan, P.C.

20080044365 - Concave or annular particles of silicone materials for increasing the sun protection factor of aqueous photoprotective compositions comprising same: Sunscreen compositions having increased SPF contain at least one aqueous phase, at least one organic UV screening agent and/or at least one inorganic UV screening agent, notably at least one wetting agent, and an effective SPF-increasing amount of concave or annular particles of a silicone material, formulated into a physiologically... Agent: Buchanan, Ingersoll & Rooney PC

20080044366 - Compositions for application to the skin, to the lips, to the nails, and/or to hair: The present disclosure relates to compositions comprising particles of at least one composite pigment, the particles comprising an inorganic core which is at least partially coated with at least one organic coloring substance, wherein the composition has a covering power ranging from 1 to 25, and wherein the at least... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080044367 - Cosmetic compositions with film forming polymer: A cosmetic composition for coloring, conditioning, or beautifying keratinous surfaces comprising at least one film forming polymer which comprises vinyl ester monomers.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20080044368 - Durable hair treatment composition: Topical compositions for treating hair are presented. The compositions comprise functionalized silicones having defined physicochemical properties that exhibit superior conditioning duability on hair than previously known silicone based conditioners, especially where the hair has been previously damaged through chemical treatments, such as occurs during permanent dyeing, bleaching and permanent waving.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080044370 - Composition for scalp and hair of scalp: An object of the present invention is to provide scalp and hair of scalp composition which realizes hair growing, hair growth or the like by arranging the scalp environment without inhibiting the function of sebaceous membrane and dark cell (superficial type cell) of scalp. To achieve the object, the present... Agent: Oliff & Berridge, PLC

20080044372 - Transfer-resistant makeup removing compositions: The invention relates to a cleansing composition suitable for topical application to human skin, more particularly to an oil-based cleansing composition containing a silicone elastomer gelling agent for removal of make-up from the skin.... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20080044373 - Cosmetic composition for the lips, combining a phosphate surfactant and a silicone polymer: The present invention relates to a cosmetic composition for the lips,